SIRPA and neoplasm: We aimed to evaluate a novel treatment regimen for this population by blocking the CD47/SIRP “do not eat me” signal between tumor cells and phagocytes with evorpacept, providing a tumor-directed pro-phagocytic opsonizing signal with cetuximab and synergistically activating the adaptive immune system with pembrolizumab.